Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Bullboard Posts
Post by ready2go1on Dec 17, 2009 10:06pm
427 Views
Post# 16599546

News

NewsIts clear to see that news drives the market, we are in a time where investors have no time to sit and wait for approvals and new products to hit the market.  I have watched a number of stocks that I have held in the past hit 52 wk highs as I sit and wait for are friend to make their move. I am confident that we will see it and optimistic about the future but it will take a little more time. These other stocks have made there move but have already started to pull back. We should see CUR make a lasting move that they will build on. PCA3 is the ticket and Gen-Probe is spending the money needed to get it going in Europe and they will promote it like crazy once it receives FDA approval here in the states. They have already been hard at work getting the test ready for Panther which will be another big step. The stock has not moved with where we are in terms of PCA3 and I do, like others on this board, blame the company for not getting the word out.
      I wanted to add that all the stories about over testing and the past studies that have come out looking at prostate and breast cancer screening, are actually positive for PCA3. PSA is all that physicians have and they will be more than happy to use PSA3, There are also studies taking place that are looking the right now that are looking at pca3 score and how it relates to tumor grade.
     We should have some good in March when GSK speaks at ASCO about their study and pca3.    I wish I knew what the trigger will be and when it will come but I do know that we are in the home stretch and it should come at some point.
Bullboard Posts